Harmony Biosciences Holdings, Inc. - Common Stock (HRMY)
37.86
+0.57 (1.53%)
NASDAQ · Last Trade: Aug 23rd, 2:37 PM EDT
Harmony Biosciences (HRMY) is a value stock with strong fundamentals: undervalued P/E, high profitability, robust financial health, and impressive growth metrics.
Via Chartmill · August 22, 2025
Harmony Biosciences (HRMY) offers strong growth, solid valuation, and financial health, making it an ideal pick for Affordable Growth investors seeking high potential at reasonable prices.
Via Chartmill · August 13, 2025
Harmony Biosciences (HRMY) offers strong growth potential with solid fundamentals, high profitability, and a bullish technical setup, making it an attractive stock for investors.
Via Chartmill · August 9, 2025
Harmony Biosciences (HRMY) is undervalued with strong fundamentals—low P/E, high profitability, solid financials, and robust growth, making it a prime value investing opportunity.
Via Chartmill · July 26, 2025
Harmony Biosciences (HRMY) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the pharmaceutical sector.
Via Chartmill · July 19, 2025
Via Benzinga · July 10, 2025
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal.
Via Investor's Business Daily · July 10, 2025
HARMONY BIOSCIENCES (HRMY) is an undervalued pharmaceutical stock with strong profitability, financial health, and growth potential, making it a candidate for value investors.
Via Chartmill · July 2, 2025
HARMONY BIOSCIENCES (HRMY) offers strong growth, solid profitability, and an attractive valuation, making it a compelling choice for investors seeking affordable growth stocks in the pharmaceutical sector.
Via Chartmill · June 27, 2025
Harmony Biosciences (HRMY) presents a compelling value opportunity with strong profitability, financial health, and growth—all at an attractive valuation.
Via Chartmill · June 11, 2025

Harmony Biosciences (HRMY) offers strong growth, solid profitability, and an attractive valuation, making it a standout in the pharmaceuticals sector.
Via Chartmill · June 6, 2025

Harmony Biosciences (HRMY) shows strong growth, profitability, and a bullish technical pattern, making it a stock worth watching in the pharmaceuticals sector.
Via Chartmill · May 29, 2025
Harmony Biosciences (HRMY) shows strong growth, profitability, and financial health while trading at an attractive valuation, making it a potential pick for value investors.
Via Chartmill · May 21, 2025
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY) offers strong growth, reasonable valuation, and solid financial health, making it an attractive option for investors seeking affordable growth stocks.
Via Chartmill · May 15, 2025
Via Benzinga · May 6, 2025
Harmony Biosciences Holdings (NASDAQ:HRMY) is a strong affordable growth stock with high growth, solid profitability, and attractive valuation. Learn why it stands out in the pharmaceutical sector.
Via Chartmill · May 2, 2025
Harmony Biosciences Holdings (NASDAQ:HRMY) – A Strong Affordable Growth Stock Candidate
Via Chartmill · April 30, 2025
Uncover the potential of HARMONY BIOSCIENCES HOLDINGS, an undervalued stock. NASDAQ:HRMY maintains a strong financial position and offers an appealing valuation.
Via Chartmill · April 29, 2025
Discover HARMONY BIOSCIENCES HOLDINGS, an undervalued growth gem. NASDAQ:HRMY is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Via Chartmill · April 24, 2025
Via Benzinga · April 8, 2025
As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · April 4, 2025